Jemperli Meets Phase II Rectal Cancer Goal, Putting GSK on Path to Accelerated US Review

summarizeSummary

Jemperli met its primary endpoint in a registrational phase II trial for dMMR/MSI-H locally advanced rectal cancer, showing sustained complete responses at 12 months. GSK will pursue accelerated US approval, potentially offering a chemo- and surgery-sparing option.

check_boxKey Events · Product Development and Regulatory · GSK

• Phase II AZUR-1 Trial Met Primary Endpoint

  In 154 patients with stage II/III dMMR/MSI-H locally advanced rectal cancer, Jemperli monotherapy delivered a clinically significant sustained clinical complete response rate at 12 months (cCR12).

• Potential to Eliminate Chemo, Radiation, and Surgery

  These results position Jemperli as the first immunotherapy that could spare patients from standard treatments, which often lead to permanent colostomy, infertility, and other quality-of-life burdens.

• Regulatory Pathway Accelerated

  Data will be shared with global regulators, including for accelerated review in the US, where Jemperli already holds Breakthrough Therapy and Fast Track designations for this indication.

• Builds on Prior Memorial Sloan Kettering Research

  The AZUR-1 findings confirm and expand on earlier collaborative research that first demonstrated dostarlimab's ability to achieve clinical complete responses without other treatments in this patient group.

auto_awesomeAnalysis · GSK · Life Sciences

In dMMR/MSI-H locally advanced rectal cancer, standard chemo-radiation and surgery often leave patients with lifelong morbidity. Jemperli (dostarlimab) achieved sustained clinical complete responses at 12 months, potentially becoming the first immunotherapy to spare patients from those interventions. GSK plans to share data with regulators, including for accelerated US review, adding a new indication to a drug already generating strong oncology momentum.